<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60350">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01849835</url>
  </required_header>
  <id_info>
    <org_study_id>tongji10us</org_study_id>
    <secondary_id>tongji10-us1</secondary_id>
    <nct_id>NCT01849835</nct_id>
  </id_info>
  <brief_title>A Test of the Comparison Between Trans-rectal and Trans-perineal Biopsy of Prostate</brief_title>
  <acronym>RCT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized controlled trial (RCT) is to compare the two ways
      (tras-rectal and trans-perineal) to perform prostate biopsy from the rate of Positive
      detection, complications, pain level, operation time and costs et al.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>the rate of positive detections</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the incidence rate of each complication</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>pain level assessed by visual analogue scale</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Complication</condition>
  <arm_group>
    <arm_group_label>trans-rectal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trans-rectal to perform the prostate biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trans-perineal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trans-perineal to perform the prostate biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>trans-rectal to perform the prostate biopsy</intervention_name>
    <description>the puncture points are at the rectal</description>
    <arm_group_label>trans-rectal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>trans-perineal to perform the prostate biopsy</intervention_name>
    <description>the puncture points are at the perineal</description>
    <arm_group_label>trans-perineal</arm_group_label>
    <other_name>the puncture points are at the perineal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  prostate-specific antigen &gt; 4ng/ml

          -  Palpation is positive

        Exclusion Criteria:

          -  older than 80y

          -  prostate-specific antigen &gt; 100 ng/ml
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>guo lehang, phd</last_name>
    <phone>+8613764538305</phone>
    <email>gopp1314@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>10Th Hospital of Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>guo lehang, phd</last_name>
      <phone>+8613764538305</phone>
      <email>gopp1314@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>xu huixiong, phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 4, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Le-hang Guo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>rate of positive detection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
